

Applicants :

Virginia M. Litwin, et al.

U.S. Serial No.:

09/891,062 June 25, 2001

Filed Page 3

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of the claims in the application.

In the Claims


Please amend as follows:

Claims 1-39 (Cancelled).

(Amended) A method of inhibiting HTV-1 infection of a --40. CD4+ cell which comprises contacting the CD4+ cell with an amount of a monoclonal antibody or portion thereof effective to (a) specifically inhibit 67% or greater of fusion of a CD4+ PM-1 cell to a HeLa cell expressing envelope glycoprotein from HIV-1_{JR-FL}, and (b) inhibit 18% or less of fusion of a CD4+ SUP-T1 cell to a HeLa cell expressing envelope protein from HIV- $\mathbf{1}_{\text{LAI}}$, wherein the antibody (i) does not crossreact with HIV-1 envelope glycoprotein or CD4, (ii) reacts with an antigen on the surface of a PM-1 cell, and (iii) does not react with an antigen on the surface of a SUP-T1 cell, and (iv) is at least as active as monoclonal antibody PA-7 in inhibiting fusion as recited in (a) above and less active than monoclonal antibody PA-6 in inhibiting fusion as recited in (b) above, so as to thereby inhibit HIV-1 infection of the CD4+ cell.--

- --41. (Previously presented) The method of claim 40, wherein the monoclonal antibody is a chimeric monoclonal antibody.--
- --42. (Previously presented) The method of claim 40, wherein the monoclonal antibody is humanized.--

anid



Virginia M. Litwin, et al.

U.S. Serial No.: Filed

09/891,062

Page 4

June 25, 2001

--43. (Previously presented) The method of claim 40, wherein the monoclonal antibody is a human monoclonal antibody .--

- (Previously presented) The method of claim 40, wherein the portion of the monoclonal antibody is a single chain antibody or an antigen binding fragment. --
- --45. (Previously presented) The method of claim 40, wherein the monoclonal antibody is labeled with a detectable marker .--
- --46. (Previously presented) The method of claim 45, wherein the detectable marker is a radioactive isotope, enzyme, dye or biotin.--

--47. (Previously presented) The method of claim 40, wherein the CD4+ cell is present in the subject and the contacting is effected by administering the monoclonal antibody or portion thereof to the subject. --